NewsRelease

Twojournal articles cite HemogloBind™ to remove analyticalinterferences from Hemoglobin

MONMOUTHJUNCTION, NJ, September8, 2021 -- Biotech Support Group reports on two journal articlesdescribing the simplicity and efficiency of their HemogloBind™sample preparation technology for removing analytical interferences,in the measurements of total urine protein, and western blotrespectively. The first citation is:

Juriasingani,Smriti, et al. "Evaluatingthe Effects of Subnormothermic Perfusion with AP39 in a NovelBlood-Free Model of Ex Vivo Kidney Preservation andReperfusion." InternationalJournal of Molecular Sciences 22.13(2021): 7180.

Thisstudy evaluated whether adding hydrogen sulfide donor AP39 toHemopure, a blood substitute, during subnormothermic perfusionimproves kidney outcomes. Because of the added Hemopure, the articlestates, “Most of the urine samples collected were heavilypigmented, due to the presence of hemoglobin from the Hemopure, whichprevented the use of conventional urinalysis methods. A 1:3 dilutionof urine in Hemoglobind (Biotech Support Group, Monmouth Junction,NJ, USA) allowed us to obtain clearer urine samples after 10 min ofvigorous shaking and centrifugation at 12,000× g.“The investigation concluded that subnormothermic perfusion at 21 °Cwith Hemopure + 200 nM AP39 improves renal outcomes. 

Thesecond citation is:

D'Alessandro,Angelo, et al. "Hematologicand systemic metabolic alterations due to Mediterranean type II G6PDdeficiency in a novel murine model." bioRxiv (2021).

Deficiencyof Glucose 6 phosphate dehydrogenase (G6PD) is the single most commonenzymopathy, present in approximately 400 million humans (e.g. 5% ofhumans). G6PD deficiency is associated with kidney disease, diabetes,pulmonary hypertension, immunological defects, and neurodegenerativediseases. To generate a more accurate model of deficiency, thehuman sequence for a severe form of G6PD deficiency (Med -) wasknocked into the murine G6PD locus and confirmed by Western blot. Thearticle states “Briefly, RBCs were washed 3 times PBS, followed bytransfer of one part washed RBCs into three parts water, followed byend over end rotation for 5 min at room temperature to lyse the RBCs.Lysed RBCs were then mixed 1:1 with HemogloBind (Biotech SupportGroup), followed by end over end rotation for 10 min at roomtemperature. HemogloBind and bound hemoglobin were pelleted bycentrifugation, and supernatants subjected to an additionalhemoglobin depletion with HemogloBind. Supernatants were used forwestern blotting.” The authors’ findings both establish a newmouse model of G6PD deficiency that more accurately reflects humanG6PD deficiency, and also advance our basic understanding of alteredmetabolism in this setting. 

“Thelarge amount of hemoglobin in many samples presents a specialchallenge for quantitative analysis. These two articles illustratethe versatility of HemogloBind™ to reduce the interferenceassociated with large concentrations of hemoglobin, withoutcompromising the recovery and analysis of the protein(s) ofinterest.” states Swapan Roy, Ph.D., President and Founder ofBiotech Support Group.

Clickhere for more information on HemogloBind™

Clickhere for more information on all of our Hemoglobin Removal products

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HmoVoid™ for hemoglobin removal, andNuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on personalized medical decisions forcancer and Covid-19 patients. For more information, go tohttp://www.biotechsupportgroup.com.

ForBusiness Development,contact:MatthewKuruc 732-274-2866,[email protected]